We all are impacted by, and reap the benefits of, medical research discoveries. From over-the-counter drugs, to healthcare policies and educational interventions, many of these advancements are a result of incredible feats, decades of work, and sometimes serendipitous events. Join us as we sit down with Harvard researchers to discuss these captivating behind-the-scenes stories of research.
Jeff Karp, PhD, Brigham and Women’s hospital, discusses the concept of radical simplicity, which he describes as “breaking down the problem into simple terms that you can test.” Karp explains how he used this approach in stem cell therapy research to inform the translational and commercialization process.
Jeff Karp, PhD, is a professor of medicine at Brigham and Women’s Hospital, Harvard Medical School. He is also a principal faculty member at the Harvard Stem Cell Institute, and an affiliate faculty member at the Broad Institute and at the Harvard-MIT Division of Health Sciences and Technology.
Karp works in the fields of drug delivery, medical devices, stem cell therapeutics, and tissue adhesives. He has published over 125 peer-reviewed papers, with >18,500 citations, and has given over 300 invited lectures. He has over 100 issued or pending national and international patents. Several technologies developed in his lab have led to multiple products currently in development or on the market and to the launch of seven companies that have raised over $300 million in funding. Technologies include high-tech skincare, tissue adhesives and 3D printed biomedical devices, immunomodulation with biologically responsive materials, small molecule regenerative therapeutics with an initial target of hearing loss, cannabinoid therapeutics, biomedical devices to improve child safety, needles that automatically stop when they reach their target, and a bioengineered luminal coating for controlled GI targeting.
“I think some of the most exciting areas have been where there are no guideposts,” says Martha Shenton of Brigham and Women’s Hospital. In this podcast, Shenton reflects on her career in neuroimaging, discusses her research looking at schizophrenia, and gives advice to aspiring researchers.
Martha Shenton, PhD, is a professor in psychiatry and radiology at Brigham and Women’s Hospital, founding director of the Psychiatry Neuroimaging Laboratory at Harvard Medical School, and a health scientist at the VA Boston Healthcare System. Shenton and her team have been developing and applying MRI techniques to the study of schizophrenia, and she is now working to advance our understanding of mild traumatic brain injury using advanced MRI techniques. Shenton has authored over 300 peer-reviewed empirical articles and proceedings, and has received numerous awards throughout her career.
In our first episode Dr. Elliott Antman, Associate Dean of Clinical and Translational Research at Harvard Medical School, shares the fascinating story of how medical issues in cows led to the discovery of one of the most widely used drugs in America today.
Bio: Elliott Antman, MD, is professor of medicine and an associate dean for Clinical/Translational Research at Harvard Medical School, a senior investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, and a senior physician in the Cardiovascular Division of Brigham and Women’s Hospital in Boston, Massachusetts. He was president of the American Heart Association (2014-2015) and is now the immediate past president. The American Heart Association honored him with the 2016 Paul Dudley White Award.